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SUMMARY 
A highly sensitive gas chromatographic assay is described for the simultaneous determination of 
gallopamil, a calcium channel blocking agent, and its major metabolite, norgallopamil. A multi-step 
extraction procedure is employed followed by on-column capillary gas chromatographic analysis using 
nitrogen-selective detection. Acetylation of norgallopamil is performed to enable accurate quantifi- 
cation of the metabolite. Linearity was achieved over the range l-50 ng/ml for both analytes. Assay 
specificity, precision and accuracy were investigated. 
INTRODUCTION 
Gallopamil, a methoxy analogue of verapamil, is a calcium antagonist with a 
reported activity three to five times greater than verapamil in animal experi- 
ments [ 11. Studies have shown that similar to verapamil, gallopamil undergoes 
extensive first-pass metabolism resulting in low plasma concentrations of drug 
as well as a large number of N-demethylated and 0-demethylated metabolites 
(Fig. 1). The efficacy of gallopamil has been demonstrated in the treatment of 
angina pectoris. Beneficial effects have also been shown in patients with various 
cardiac arrhythmias and mild to moderate hypertension [ 11. 
Few papers have been published concerning the analysis of gallopamil in plasma. 
A gas chromatographic (GC) method for measuring gallopamil with a detection 
limit of 5.0 ng/ml has been reported [ 21. However, since concentrations as low 
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Fig. 1. Structures of gallopamil, several metabolites and internal standard. 
as 1-2 ng/ml have been observed in subjects taking therapeutic doses of gallo- 
pamil [ 31, no valid pharmacokinetic parameter estimates can be made using the 
above approach. 
Two high-performance liquid chromatographic (HPLC ) methods using fluo- 
rescence detection for the simultaneous determination of gallopamil and its ma- 
jor metabolite norgallopamil in plasma have been reported by our laboratory [ 41 
and by Nieder and Jaeger [ 51. A more recent publication describes a procedure 
for the HPLC analysis of gallopamil alone [ 61. Each of these methods demon- 
strated a detection limit less than 1 ng/ml for the analytes. 
This paper describes a specific and sensitive GC method enabling the quanti- 
fication of both gallopamil and norgallopamil with a detection limit similar to 
HPLC methods. 
EXPERIMENTAL 
Standards and reagents 
Gallopamil (D600), norgallopamil (D845) and five minor metabolites were 
obtained as hydrochloride salts from Knoll (Ludwigshafen, F.R.G. ) . The internal 
standard (Fig. l), a structural analogue of verapamil (D517), was supplied by 
Knoll Pharmaceutical (Whippany, NJ, U.S.A.). Stock solutions of gallopamil, 
norgallopamil and internal standard were prepared in methanol and stored at 
5 “C in amber silane-treated volumetric flasks. Methanolic dilutions of gallopamil 
and norgallopamil used to spike plasma for calibration standards were prepared 
immediately before use. Working solutions of the internal standard were pre- 
pared in water. 
All solvents were HPLC grade unless otherwise stated. Pentane, methylene 
chloride, isopropanol, butyl acetate, methanol, toluene and water were from Bur- 
dick and Jackson Labs. (Muskegon, MI, U.S.A. ). Potassium hydroxide and acetic 
anhydride were supplied by Baker (Phillipsburg, NJ, U.S.A. ); hydrochloric acid 
was obtained from Fisher (Fair Lawn, NJ, U.S.A.). 
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Glassware 
All glassware used to prepare extracts were methanol-rinsed, dried and silane- 
treated with 10% dichlorodimethylsilane (Kodak) in toluene. Disposable glass 
culture tubes (16 x 125 mm) and disposable glass conical tubes (15 ml), both 
with PTFE-lined caps, were obtained from American Scientific Products (McGaw 
Park, IL, U.S.A. ). 
Chromatographic conditions 
Analyses were carried out on a Varian Model 6000 gas chromatograph (Varian, 
Walnut Creek, CA, U.S.A.) equipped with a thermionic specific detector. Oper- 
ating parameters for the analysis of gallopamil and norgallopamil are summa- 
rized in Table I. 
Extraction procedure 
Plasma (1 ml) and 15 ng of the internal standard in water (100 ~1) were pi- 
petted into 16 x 125 mm silane-treated culture tubes with PTFE-lined screw caps. 
The plasma samples were adjusted to pH 13 by the addition of 100 yl of 2 M 
potassium hydroxide, then extracted with 5 ml of pentane-methylene chloride- 
isopropyl alcohol (39 : 10 : 1) . Mixing was accomplished by rotating the tubes on 
a Glas-Co1 rotator (Glas-Col, Terre Haute, IN, U.S.A.) at 75 rpm for 10 min. 
After centrifugation at 1150 g for 10 min, the aqueous layer of the samples was 
frozen at -80°C in a Revco freezer. The organic layer was poured into a clean 
silane-treated 16x 125 mm culture tube and back-extracted with 2 ml of 1 M 
hydrochloric acid by reciprocal shaking for 10 min on an Eberbach shaker (Eber- 
bath, Ann Arbor, MI, U.S.A.). Following centrifugation at 1150 g for 5 min, the 
samples were frozen at -80°C. After removing the tubes from the deep-freeze, 
the organic layer was discarded. The samples were made alkaline with 300 ~1 of 









15 mX0.32 mm I.D. DB-1,0.25 pm film 
(J&W Scientific) 
On-column injector (J&W Scientific) 
continuous helium purge, 5 ml/min 
1 Pl 
Helium, maintained at constant 30 p s.i.; 
helium make-up, 30 ml/min; 
air, 175 ml/min; 
hydrogen 4.5 ml/min 
Injector, ambient; 
detector, 300” C; 
oven, 130 to 150°C at 35”C/min, 
150 to 200°C at SO”C/min, 
200 to 300°C at 20”C/min, hold 2 min 
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ride (4 : 1) for 10 min on an Eberbach shaker. The samples were again frozen and 
the organic layer was decanted into a silane-treated 15 ml conical tube. Isopropyl 
alcohol (250 ,~l ) was added to each tube. The samples were vortexed and evapo- 
rated to dryness under nitrogen at 35’ C. Acetic anhydride (50 ~1) was added to 
each tube and allowed to stand 15 min. The acetic anhydride was evaporated 
under nitrogen at 35°C. The samples were reconstituted in 25 ~1 of butyl acetate. 
A 1 ~1 volume was injected for analysis. Peak-height ratios were recorded. Cali- 
bration of the data was performed using weighted least-squares linear regression 
analysis [ 71. 
RESULTS AND DISCUSSION 
The development of a GC method for the analysis of gallopamil and norgallo- 
pamil presented a unique challenge. Since gallopamil is three to five times more 
potent than verapamil, lower doses are administered to patients resulting in lower 
concentrations of parent drug and metabolites. 
In order to achieve a quantifiable detection limit of 1 ng/ml for gallopamil, a 
capillary GC system was developed in order to take advantage of the high resolv- 
ing power, enhanced sensitivity and inertness of capillary columns. On-column 
injection was chosen as the technique which would yield the most precise and 
accurate quantification of low plasma concentrations. A multi-step sample work- 
up was developed to produce highly pure extracts for analysis. 
The quantifiable limit for both gallopamil and norgallopamil was 1 ng/ml. Lin- 
earity was achieved over the concentration range l-50 ng/ml. Intra-assay preci- 
sion and accuracy were evaluated from the analyses of six plasma samples at three 
concentrations over the range l-50 ng/ml for both gallopamil and norgallopamil. 
Accuracy was within 10% of theoretical at each concentration for gallopamil. The 
coefficient of variation (C.V. ) was < 10%. Accuracy values for norgallopamil were 
within 12% of the theoretical concentrations and the coefficient of variation 
ranged from 5.7 to 17.3%. The results are summarized in Table II. 
Inter-day assay variability was also investigated. The accuracy of the method 
TABLE II 
INTRA-DAY ASSAY PRECISION AND ACCURACY OBTAINED FOR GALLOPAMIL AND 
NORGALLOPAMIL IN PLASMA BY CAPILLARY GC ANALYSIS 
Compound Concentration n Concentration found C.V. 




Gakpamil 1.0 6 0.90 f 0.09 10 90.0 
25.8 6 26.2 t2.1 8.0 102 
49.8 6 51.1 f2.7 5.3 103 
Norgallopamil 1.0 6 0.88 f 0.05 5.7 88.0 
26.5 6 27.8 1k4.8 17.3 105 
51.6 6 49.8 f3.3 6.6 96.5 
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TABLE III 
INTER-DAY ASSAY PRECISION AND ACCURACY OBTAINED FOR GALLOPAMIL AND 
NORGALLOPAMIL IN PLASMA BY CAPILLARY GC ANALYSIS 
Compound 
Gallopamil 
Concentration n Concentration found C.V. 
added (mean+ S.D.) (%) 
(x/ml) (w/ml) 
1.0 24 0.97 * 0.12 12.4 
5.0 12 4.8 f0.2 4.2 
25.8 38 25.8 f2.2 8.5 







Norgallopamil 1.0 24 0.92 * 0.20 21.6 90.6 
5.1 12 5.2 kO.4 7.7 102 
26.5 38 27.0 k3.9 14.4 102 
51.6 36 48.3 rk5.2 10.8 93.6 
was within 10% of the theoretical plasma concentrations for gallopamil and nor- 
gallopamil. Assay precision showed a coefficient of variation ranging from 4.2 to 
12.4% for gallopamil and 7.7 to 21.6% for norgallopamil over a similar range 
(Table III). 
The method was shown to be specific for the internal standard and analytes. 
Fig. 2 illustrates chromatograms obtained from the analysis of blank plasma and 
plasma spiked with internal standard, gallopamil and norgallopamil. Retention 
times were 5.4,5.9 and 6.9 min, respectively. No interference was observed from 
plasma components. The method was also specific to four known metabolites (I- 
IV), illustrated in Fig. 1, as well as an N-desalkyl metabolite resulting from the 
loss of the dimethoxyphenylethyl ring from gallopamil. Extraction studies dem- 
onstrated that at a pH of 13, the 0-desmethyl metabolites (I-IV) do not extract 
from plasma. Furthermore, these metabolites do not co-chromatograph with gal- 
lopamil, norgallopamil and the internal standard as is illustrated in Fig. 3. 
Despite the extensive sample clean-up procedure, routine column maintenance 
was necessary when chromatographic resolution of peaks deteriorated or signif- 
icant on-column build-up of plasma components occurred as evidenced by exces- 
sive column bleed. To accomplish this 20-30 cm of the injector end of the column 
was removed. Approximately 2-3 m of the column could be removed without loss 
of peak resolution. 
A common property of amines not often addressed in publications is their abil- 
ity to adsorb to glass surfaces during the sample work-up [ 81. The adsorption 
tendency of gallopamil was observed in our initial method development during 
the evaporation step of the sample work-up. In order to prevent substantial loss 
of drug, isopropyl alcohol was added to the final extract before evaporation of the 
solvent. Additionally, silane-treated glassware was used as another measure to 
avoid loss of drug. 
Acetylation of norgallopamil with acetic anhydride, a technique used by other 
investigators [ 9,101, enabled accurate quantification of this metabolite. Unlike 
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Fig. 2. (A) Chromatogram of blank plasma spiked with 15 ng internal standard (1). (B) Chroma- 
togram of a plasma extract containing 15 ng internal standard (1 ), 7 ng of gallopamil (2) and 7 ng of 
norgallopamil (3) per ml of plasma. 
gallopamil and the internal standard, underivatized norgallopamil, a secondary 
amine, is highly reactive to column active sites. Acetylation of this metabolite 
proved to be a simple technique for conversion of this compound to a less reactive 
n-acetyl derivative. Derivatization of norgallopamil also shifted it away from gal- 
lopamil, providing greater resolution between the two components. Fig. 4 illus- 
trates a chromatogram of derivatized and underivatized norgallopamil relative to 
gallopamil and the internal standard. 
We have demonstrated the utility of the assay for measuring gallopamil and 
norgallopamil in healthy volunteers participating in controlled bioavailability 
studies. Additional validation of this method is required before it can be used to 
monitor plasma concentrations in patients who are concurrently taking addi- 
tional medications. Fig. 5 represents plasma concentration-time profiles of gal- 
lopamil and norgallopamil for a subject administered a 5 mg tablet of gallopamil. 
The half-lives of gallopamil and norgallopamil were 1.9 and 3.2 h, respectively. 
This paper presents a sensitive and specific capillary GC method for the anal- 
ysis of gallopamil and norgallopamil. This approach may be used as an alternative 
to HPLC methods or as the basis for a GC approach to measuring other metab- 
olites of gallopamil. 
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Fig. 3. Chromatogram of a derivatized sample of authentic standards containing internal standard 
(1)) gallopamil (2)) norgallopamil (3 ) , N-desalkyl metabolite (4)) metabolite II (5)) metabolite I 
(6), metabolite III ( 7 ) and metabolite IV (8). 
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Fig. 4. Chromatogram of internal standard ( 1) , gallopamil (2), underivatized norgallopamll (3 ) and 
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Fig. 5. Plasma concentration-time profile of gallopamil ( o ) and norgallopamil ( l ) obtained from a 
volunteer after administration of a tablet containing 5 mg gallopamil. 
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